FDA Rejects Anaphylm Filing Citing Pouch and Film Placement Issues; Aquestive Targets Q3 2026 Resubmission
FDA declined to approve Aquestive’s Anaphylm sublingual film, citing human factors validation deficiencies in pouch opening and film placement. The company will redesign packaging, update labeling, run new human factors and PK studies, and aims to resubmit in early Q3 2026.
1. Analyst Price Target and Upside Potential
On February 2, 2026, New Street Research assigned a price target of twelve dollars for AQST shares, implying an upside of roughly 193% from recent levels. This projection reflects confidence in the company’s differentiated oral film technology and the anticipated milestone events surrounding its lead candidate. Despite the recent regulatory setback, the sizeable upside identified by New Street underscores bullish sentiment among equity analysts covering the specialty pharmaceutical sector.
2. FDA Complete Response Letter and Company Actions
Aquestive Therapeutics received a Complete Response Letter for its Anaphylm (dibutepinephrine) sublingual film, with the FDA citing human factors deficiencies in the film’s pouch design and user instructions. To address these issues, the company has redesigned the pouch opening mechanism, updated labeling and instructions for use, and plans to conduct a new human factors validation study. Parallel pharmacokinetics work will verify that these modifications do not alter drug performance. Management expects to resubmit the New Drug Application in early Q3 2026, targeting a rapid review pathway.
3. Stock Performance and Market Metrics
Since the FDA decision was announced, AQST shares have rallied by nearly 39%, reflecting investor focus on the company’s corrective action plan. Over the past twelve months, the stock has traded between a low of 2.12 and a high of 7.55, demonstrating elevated volatility typical of clinical-stage biopharma names. Market capitalization stands at about 500 million, with average daily trading volumes approaching 60 million shares, indicating strong retail and institutional liquidity.
4. Upcoming Milestones and Regulatory Timeline
Looking ahead, Aquestive anticipates completing its human factors and supportive pharmacokinetics studies by mid-2026, with an NDA resubmission planned in early Q3 and a potential FDA decision in H1 2027. The company also aims to file for marketing authorization in Europe and Canada in the second half of 2026, and to engage with the U.K. regulator in Q1. Success at these regulatory checkpoints will be pivotal for advancing Anaphylm toward commercialization and for unlocking near-term value drivers for shareholders.